Adobe
ADBE
Lennar Corp
LEN
Petroleo Brasileiro SA Petrobras
PBR
Apple
AAPL
D.R. Horton
DHI
US Stock MarketDetailed Quotes
ALNY Alnylam Pharmaceuticals
- 242.500
- -0.750-0.31%
Close Dec 26 16:00 ET
- 244.000
- +1.500+0.62%
Pre 07:42 ET
31.28BMarket Cap-92.56P/E (TTM)
244.820High240.430Low358.61KVolume241.780Open243.250Pre Close86.90MTurnover0.28%Turnover RatioLossP/E (Static)128.98MShares304.39052wk High966.14P/B31.14BFloat Cap141.97552wk Low--Dividend TTM128.43MShs Float304.390Historical High--Div YieldTTM1.81%Amplitude3.650Historical Low242.322Avg Price1Lot Size
About Alnylam Pharmaceuticals Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Company Profile
SymbolALNY
Company NameAlnylam Pharmaceuticals
Listing DateMay 27, 2004
Issue Price6.00
Founded2002
CEODr. Yvonne L Greenstreet, MB.Ch.B.
MarketNASDAQ
Employees2100
Fiscal Year Ends12-31
Address675 West Kendall Street,Henri A. Termeer Square
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02142
Phone1-617-551-8200
Websitehttp://www.alnylam.com
Company Executives
- Name
- Position
- Salary
- Dr. Yvonne L Greenstreet, MB.Ch.B.
- Director and Chief Executive Officer
- 8.90M
- Kevin Joseph Fitzgerald, PhD
- Executive Vice President, Chief Scientific Officer and Head, Early Research and Early Development
- --
- Dr. Pushkal P. Garg, M.D.
- Chief Medical Officer and Executive Vice President, Development and Medical Affairs
- 3.23M
- Dr. Akshay K. Vaishnaw, M.D.,PhD
- Chief Innovation Officer
- 3.32M
- Jeffrey V. Poulton
- Executive Vice President, Chief Financial Officer and Principal Accounting Officer
- 3.22M
- Tolga Tanguler
- Chief Commercial Officer
- 2.87M
- Amy W. Schulman
- Chairman of the Board
- 531.36K
- Michael W. Bonney
- Director
- 467.23K
- Dr. Olivier Raymond Brandicourt, M.D.
- Independent Director
- 480.96K
- David E.I. Pyott, M.B.A.,M.D.
- Independent Director
- 477.21K
- Colleen F. Reitan
- Independent Director
- 489.15K
- Dr. Elliott Sigal, M.D.,PhD
- Independent Director
- 470.11K
- Dr. Margaret A. Hamburg, M.D.
- Independent Director
- 471.39K
- Dr. Carolyn R. Bertozzi, PhD
- Independent Director
- 668.94K
- Peter N. Kellogg
- Independent Director
- 658.72K
- Dr. Phillip A. Sharp,PhD
- Independent Director
- 502.21K
- Dr. Dennis A. Ausiello, M.D.
- Independent Director
- 477.21K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.